Pasithea Therapeutics (KTTA) News Today $3.24 +0.05 (+1.57%) (As of 12:45 PM ET) Add Compare Share Share Headlines Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Pasithea Therapeutics announces SRC recommended proceeding to cohort 4November 20 at 1:54 PM | markets.businessinsider.comPasithea Therapeutics Advances PAS-004 Clinical Trial to Next Dose Level Following Positive Safety Review FindingsNovember 20 at 8:01 AM | quiverquant.comPasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced CancerNovember 20 at 7:02 AM | globenewswire.comPasithea Therapeutics (NASDAQ:KTTA) Shares Up 2.4% - Here's WhyNovember 16, 2024 | americanbankingnews.comCrude Oil Down Over 2%; US Initial Jobless Claims FallSeptember 27, 2024 | msn.comDow Surges Over 250 Points; Accenture Earnings Top ViewsSeptember 27, 2024 | benzinga.comPasithea Therapeutics Shares Move Higher After Positive Data for Cancer TreatmentSeptember 26, 2024 | marketwatch.comPasithea Announces Positive Initial Data From Phase 1 Trial Of PAS-004 In Advanced Cancer; Stock UpSeptember 26, 2024 | markets.businessinsider.comPasithea Therapeutics (NASDAQ:KTTA) Stock Quotes, Forecast and News SummarySeptember 26, 2024 | benzinga.comPasithea Therapeutics Announces $5 Million Private Placement Priced At-The-Market Under Nasdaq RulesSeptember 26, 2024 | globenewswire.comPasithea Therapeutics Announces Positive Initial Safety, Tolerability, Pharmacokinetic (PK), and Preliminary Efficacy Data from its Phase 1 Clinical Trial of PAS-004 in Advanced CancerSeptember 26, 2024 | globenewswire.comPasithea Therapeutics Announces Successful Completion of PAS-004 Chronic Toxicity StudiesSeptember 9, 2024 | globenewswire.comPasithea Therapeutics Announces Appointment of Dr. Rebecca Brown to its Scientific Advisory BoardSeptember 3, 2024 | globenewswire.comPasithea Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceAugust 28, 2024 | globenewswire.comKTTA Stock Earnings: Pasithea Therapeutics Reported Results for Q4 2023June 25, 2024 | investorplace.comPasithea Therapeutics to Present New Preclinical Data Showing PAS-004 Strongly Inhibits NRAS Cancer Cell Lines and Demonstrates Superior Activity in Xenograft Studies at 2024 ASCO Annual MeetingMay 28, 2024 | globenewswire.comKTTA Stock Earnings: Pasithea Therapeutics Reported Results for Q1 2024May 15, 2024 | msn.comPasithea Therapeutics Announces PAS-004 Abstract Accepted for Poster Presentation at 2024 ASCO Annual MeetingApril 29, 2024 | globenewswire.comPasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated CancersApril 24, 2024 | globenewswire.comTrading was temporarily halted for "KTTA" at 02:02 PM with a stated reason of "LULD pause."February 15, 2024 | marketbeat.comPasithea Therapeutics Announces Opening of Enrollment in the U.S. for its Phase 1 Trial of PAS-004February 13, 2024 | finance.yahoo.comPasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) PositionJanuary 8, 2024 | finance.yahoo.comPasithea Jumps as FDA Grants IND Status to Cancer TreatmentJanuary 2, 2024 | msn.comPasithea Therapeutics' IND Application For PAS-004 Gets FDA AcceptanceJanuary 2, 2024 | markets.businessinsider.comPasithea conducts 1-for-20 reverse stock split, gets FDA okay for studyJanuary 2, 2024 | seekingalpha.comPasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer PatientsJanuary 2, 2024 | finance.yahoo.comPasithea Therapeutics Stock (NASDAQ:KTTA) Dividends: History, Yield and DatesJanuary 1, 2024 | benzinga.comTrading was temporarily halted for "KTTA" at 07:12 PM with a stated reason of "News pending."January 1, 2024 | marketbeat.comPasithea Therapeutics Announces Adjournment of Reconvened Meeting of Stockholders to December 29, 2023December 28, 2023 | finance.yahoo.comPasithea Therapeutics Announces Results from 2023 Annual MeetingDecember 19, 2023 | finance.yahoo.comWhy Is Pasithea Therapeutics (KTTA) Stock Down 12% Today?December 13, 2023 | msn.comNeurology Focused Pasithea Therapeutics Stock Soars Over 150% Today - Here's WhyDecember 11, 2023 | msn.comPasithea Announces Positive In Vivo Preclinical Data For PAS-004December 11, 2023 | markets.businessinsider.comPasithea stock soars as high as 190% on preclinical dataDecember 11, 2023 | msn.comWhy Is Pasithea Therapeutics (KTTA) Stock Up 105% Today?December 11, 2023 | investorplace.comPasithea Therapeutics Announces Positive In Vivo Preclinical Efficacy Data for PAS-004 from NRAS Mutation Cancer Xenograft ModelsDecember 11, 2023 | finance.yahoo.comPasithea Therapeutics Announces Adjournment of 2023 Annual Meeting of StockholdersNovember 29, 2023 | finance.yahoo.comPasithea stock jumps 12% on update for anti-tumor drug PAS-004November 29, 2023 | msn.comPasithea Announces Receipt Of FDA Response Of Pre-IND Meeting For PAS-004 Clinical DevelopmentNovember 29, 2023 | markets.businessinsider.comPasithea Therapeutics Announces Outcome of Pre-IND Meeting with FDA for PAS-004 Clinical DevelopmentNovember 29, 2023 | finance.yahoo.comPasithea Therapeutics Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody that Targets α5β1 Integrin for the Treatment of both Sporadic and Familial ALSNovember 9, 2023 | finance.yahoo.comPasithea Therapeutics Corp. Announces Final Results of Tender OfferSeptember 14, 2023 | finance.yahoo.comPasithea Therapeutics to Participate in H.C. Wainwright 25th Annual Global Investment ConferenceSeptember 7, 2023 | finance.yahoo.comPasithea Therapeutics publishes study in Proceedings of the National Academy of Sciences (PNAS) that shows an increase in α5 integrin expression in ALS human and mouse brain tissue, and further demonstrates targeting α5 integrin results in improved survival and motor functionAugust 1, 2023 | finance.yahoo.comWhat's Happening With Pasithea Therapeutics Stock Today?July 20, 2023 | benzinga.comPasithea Therapeutics Announces Intention to Commence a $4.0 Million Tender Offer for its Common Stock at Price of $0.70 per Share in CashJuly 20, 2023 | finance.yahoo.comPasithea Therapeutics Special Committee Rejects Unsolicited Bid from Lucy Scientific Discovery, Inc.July 20, 2023 | finance.yahoo.comPasithea Therapeutics Announces Intention to Commence a $4.0 Million Tender Offer for its Common Stock at Price of $0.70 per Share in CashJuly 20, 2023 | finance.yahoo.comPasithea Therapeutics Confirms Previous Creation of Independent Special Committee of its Board of DirectorsJune 30, 2023 | finance.yahoo.comPasithea Therapeutics Announces Completion of GMP Manufacturing for PAS-004June 29, 2023 | finance.yahoo.com Get Pasithea Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KTTA and its competitors with MarketBeat's FREE daily newsletter. Email Address Blackrock’s Sending THIS Crypto Higher on Purpose (Ad)It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development… YES, I WANT THE #1 CRYPTO NOW KTTA Media Mentions By Week KTTA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. KTTA News Sentiment▼0.760.47▲Average Medical News Sentiment KTTA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. KTTA Articles This Week▼40▲KTTA Articles Average Week Get Pasithea Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KTTA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Vaccinex News TransCode Therapeutics News IN8bio News Aprea Therapeutics News TherapeuticsMD News Akari Therapeutics News Mannatech News Minerva Neurosciences News Kazia Therapeutics News NRx Pharmaceuticals News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:KTTA) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pasithea Therapeutics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pasithea Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
